Clinical trial
Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma
NCT00003837 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- September 30, 1999
- Completion date
- November 30, 2007
- Enrollment
- 25 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.